BACKGROUND: Coagulation disorders and reperfusion of ischemic myocardium are major causes of morbidity and mortality. Lectin pathway initiation complexes are composed of multimolecular carbohydrate recognition subcomponents and 3 lectin pathway-specific serine proteases. We have recently shown that the lectin pathway-specific carbohydrate recognition subcomponent mannose-binding lectin plays an essential role in the pathophysiology of thrombosis and ischemia/reperfusion injury. Thus, we hypothesized that the endogenous mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1) that inhibits complement activation in vitro also could be an in vivo regulator by attenuating myocardial schema/reperfusion injury and thrombogenesis when used at pharmacological doses in wild-type mice. METHODS AND RESULTS: In 2 mouse models, MAP-1 preserves cardiac function, decreases infarct size, decreases C3 deposition, inhibits MBL deposition, and prevents thrombogenesis. Furthermore, we demonstrate that MAP-1 displaces MBL/ficolin-associated serine protease (MASP)-1, MASP-2, and MASP-3 from the MBL complex. CONCLUSIONS: Our results suggest that the natural, endogenous inhibitor MAP-1 effectively inhibits lectin pathway activation in vivo. MAP-1 at pharmacological doses represents a novel therapeutic approach for human diseases involving the lectin pathway and its associated MASPs.
BACKGROUND:Coagulation disorders and reperfusion of ischemic myocardium are major causes of morbidity and mortality. Lectin pathway initiation complexes are composed of multimolecular carbohydrate recognition subcomponents and 3 lectin pathway-specific serine proteases. We have recently shown that the lectin pathway-specific carbohydrate recognition subcomponent mannose-binding lectin plays an essential role in the pathophysiology of thrombosis and ischemia/reperfusion injury. Thus, we hypothesized that the endogenous mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1) that inhibits complement activation in vitro also could be an in vivo regulator by attenuating myocardial schema/reperfusion injury and thrombogenesis when used at pharmacological doses in wild-type mice. METHODS AND RESULTS: In 2 mouse models, MAP-1 preserves cardiac function, decreases infarct size, decreases C3 deposition, inhibits MBL deposition, and prevents thrombogenesis. Furthermore, we demonstrate that MAP-1 displaces MBL/ficolin-associated serine protease (MASP)-1, MASP-2, and MASP-3 from the MBL complex. CONCLUSIONS: Our results suggest that the natural, endogenous inhibitor MAP-1 effectively inhibits lectin pathway activation in vivo. MAP-1 at pharmacological doses represents a novel therapeutic approach for human diseases involving the lectin pathway and its associated MASPs.
Authors: Laura R La Bonte; Betsy Dokken; Grace Davis-Gorman; Gregory L Stahl; Paul F McDonagh Journal: Diab Vasc Dis Res Date: 2009-07 Impact factor: 3.291
Authors: Kazue Takahashi; Wei-Chuan Chang; Minoru Takahashi; Vasile Pavlov; Yumi Ishida; Laura La Bonte; Lei Shi; Teizo Fujita; Gregory L Stahl; Elizabeth M Van Cott Journal: Immunobiology Date: 2010-03-04 Impact factor: 3.144
Authors: Ian C Michelow; Mingdong Dong; Bruce A Mungall; L Michael Yantosca; Calli Lear; Xin Ji; Marshall Karpel; Christina L Rootes; Matthew Brudner; Gunnar Houen; Damon P Eisen; T Bernard Kinane; Kazue Takahashi; Gregory L Stahl; Gene G Olinger; Gregory T Spear; R Alan B Ezekowitz; Emmett V Schmidt Journal: J Biol Chem Date: 2010-06-01 Impact factor: 5.157
Authors: Krishana C Gulla; Kshitij Gupta; Anders Krarup; Peter Gal; Wilhelm J Schwaeble; Robert B Sim; C David O'Connor; Krishnan Hajela Journal: Immunology Date: 2009-12-02 Impact factor: 7.397
Authors: W Brian Gorsuch; Benjamin J Guikema; David C Fritzinger; Carl-Wilhelm Vogel; Gregory L Stahl Journal: Mol Immunol Date: 2009-09-10 Impact factor: 4.407
Authors: Charlotte B Holt; Steffen Thiel; Kim Munk; Jakob A Østergaard; Hans E Bøtker; Troels K Hansen Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-09-30
Authors: Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl Journal: Am J Pathol Date: 2014-12-04 Impact factor: 4.307
Authors: V Frauenknecht; S Thiel; L Storm; N Meier; M Arnold; J-P Schmid; H Saner; V Schroeder Journal: Clin Exp Immunol Date: 2013-07 Impact factor: 4.330
Authors: Hui-fang Zhou; Huimin Yan; Paula Bertram; Ying Hu; Luke E Springer; Robert W Thompson; John A Curci; Dennis E Hourcade; Christine T N Pham Journal: Proc Natl Acad Sci U S A Date: 2013-10-28 Impact factor: 11.205
Authors: Masayuki Ozaki; Yulin Kang; Ying Siow Tan; Vasile I Pavlov; Bohan Liu; Daniel C Boyle; Rafail I Kushak; Mikkel-Ole Skjoedt; Eric F Grabowski; Yasuhiko Taira; Gregory L Stahl Journal: Kidney Int Date: 2016-07-01 Impact factor: 10.612